LABCORP HOLDINGS INC. (LH) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $1.4M sold). 0 members of Congress reported 0 purchases vs 4 sales. Latest close $370.78 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.
Weitz Investment Management · Ariel Investments · Jensen Investment Management — 4 tracked funds hold LH. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 4 sales ($1.4M). Insider trading 0 members of Congress reported buying (0 purchases vs 4 sales). Politician trading
ORACLE CORP (ORCL) · TEXAS INSTRUMENTS INC (TXN) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · RadNet, Inc. (RDNT) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Weitz Investment Management | 1.92% | 99,050 | HELD Q3 filed Nov 12 |
| Ariel Investments | 0.97% | 349,112 | TRIMMED (-1.4%) Q3 filed Nov 13 |
| Jensen Investment Management | 0.11% | 16,050 | TRIMMED (-13.1%) Q3 filed Nov 10 |
| Mondrian Investment Partners | 0.02% | 4,268 | TRIMMED (-3.3%) Q3 filed Oct 23 |
| Maverick Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +29.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 1,055 of 8,857 filers |
| Long-only filers among them | 1,054 |
| Change vs 2026 Q1 | +36 net · 933 entered · 897 exited |
| Shares reported, all filers | 78,762,760 |
| Reported value, all filers | $21.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Services-Medical Laboratories (SIC 8071) |
| Revenue · FY2025 | $14.0B |
| Net income · FY2025 | $876.5M |
| Total assets · FY2025 | $18.4B |
| Shares outstanding | 81,100,000 |
| Market cap (at latest close) | $30.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 4, 2026.
| Shares short · Oct 15, 2026 | 2,557,656 |
| Share of shares outstanding | 3.15% |
| Days to cover | 4.22 |
Shares short at recent settlements — Jul 31, 2026: 2.1M · Aug 14, 2026: 1.9M · Aug 31, 2026: 2.1M · Sep 15, 2026: 2.4M · Sep 30, 2026: 2.7M · Oct 15, 2026: 2.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 4, 2026.
| Shares failed to deliver · Oct 14, 2026 | 36 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 36.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 4, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 4 insiders ($1.4M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Summy Amy B. | EVP, Chief Marketing Officer | Sell | 365 | $372.58 | $136.0K | SEC filing |
| Nov 10, 2026 | Caveney Brian J | EVP, Pres of BLS, CMO & CSO | Sell | 2,000 | $372.04 | $744.1K | SEC filing |
| Nov 3, 2026 | Vaughn Bryan T | EVP and President, Diagnostics | Sell | 306 | $353.70 | $108.2K | SEC filing |
| Oct 30, 2026 | Parham Richelle P | Sell | 1,078 | $361.22 | $389.4K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | KERRII B ANDERSON | Director | 3,000 | $954.4K | Aug 17, 2026 | SEC filing |
| Aug 11, 2026 | Schechter Adam H | Officer, Director | 4,669 | $1.5M | Aug 11, 2026 | SEC filing |
| Aug 4, 2026 | Summy Amy B. | Officer | 924 | $283.4K | Aug 4, 2026 | SEC filing |
| Jul 2, 2026 | Kyle Kathryn W | Officer | 92 | $26.3K | Jul 2, 2026 | SEC filing |
| Jul 2, 2026 | Vaughn Bryan T | Officer | 234 | $67.0K | Jul 2, 2026 | SEC filing |
| Jul 1, 2026 | van der Vaart Sandra D | Former Officer | 7,138 | $2.0M | Jul 1, 2026 | SEC filing |
| Jun 8, 2026 | Kyle Kathryn W | Officer | 762 | $201.1K | Jun 8, 2026 | SEC filing |
| May 11, 2026 | Schechter Adam H | Officer, Director | 5,903 | $1.5M | May 11, 2026 | SEC filing |
| May 6, 2026 | van der Vaart Sandra D | Former Officer | 6,238 | $1.6M | May 6, 2026 | SEC filing |
| Mar 27, 2026 | Meltzer Jonathan C | Officer | 839 | $224.1K | Mar 27, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Vanguard Capital Management | SC 13G | 6,201,512 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Apr 24, 2025 | BlackRock, Inc. | SC 13G/A | 6,331,017 | 7.6% | Mar 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
0 members of Congress reported buying (0 purchases vs 4 sales).
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Delaney, April McClain | House | D | 0 | 4 | Aug 25, 2026 | $100,001 - $250,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Services-Medical Laboratories (SIC 8071). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Financial Screens
· Piotroski — Financial health improved over the past year
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Earnings Stability — Small earnings swings and almost no loss years
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Piotroski — F-score: 8 · Return on assets: 4.8% · Operating cash flow: $1.6B
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.39 · Operating cash flow: $1.6B · Net income: $876.5M
· Earnings Stability — Earnings variation (CV): 0.49 · Loss years (of 10): 0 · Latest net income: $876.5M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 8 | 50.0% | +1.7% | +0.7% | +1.1% |
| Heavy exit — 3+ tracked funds sold out together | 1 | 100.0% | +5.1% | +6.2% | -1.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold LH — ranked by lift, the co-holding pattern described in Methodology: ORACLE CORP (ORCL) · TEXAS INSTRUMENTS INC (TXN) · Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · RadNet, Inc. (RDNT) · QUEST DIAGNOSTICS INC (DGX) · EXAGEN INC. (XGN) · BillionToOne, Inc. (BLLN).
6 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 4, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 28, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 21, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ORACLE CORP (ORCL) · Track Record: how the signals scored · Practice timing on LH
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.